Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 12/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064592 | 0.82 | F10 (0.44) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2065310 | 0.80 | DRD2 (0.43) | GSK3BLMNACYP1A2CYP2D6 | |
| SCHEMBL1974462 | 0.80 | MAPT (0.46) | GSK3BLMNATSHRCYP1A2ALDH1A1 | |
| SCHEMBL2065363 | 0.80 | F10 (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL1977341 | 0.79 | DRD2 (0.42) | GSK3B | |
| SCHEMBL2065085 | 0.79 | GSK3B (0.39) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2065400 | 0.78 | F10 (0.43) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2065813 | 0.78 | KCNMA1 (0.42) | GSK3BLMNACYP1A2ALDH1A1CYP2D6 | |
| SCHEMBL1832420 | 0.77 | DRD2 (0.40) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3891480 | 0.77 | GSK3B (0.46) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321316-B1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-8614219-B2 | Substituted pyrimidin-4-one derivatives | SANOFI-AVENTIS (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2321316-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
| EP-2138492-A1 | Substituted pyrimidin-4-one derivatives | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | TYMP, DHFR, DPYD | PDE2A 482/4885GSK3B 3574/4885LMNA 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.